Appistry announces agreement with PGDx to include CancerSelect panel in Appistry CloudDx

Appistry, Inc., a leading provider of tools, software, and services that bring the power of genomics to next-generation medicine, today announced an agreement with Personal Genome Diagnostics (PGDx) to include the company's CancerSelect™ panel in Appistry's recently released Appistry CloudDx™ genomics testing service. PGDx, a provider of CLIA-compliant genomics services to oncology researchers, drug developers, clinicians, and patients, is among the first organizations to offer lab-developed tests (LDTs) through Appistry's cloud-based service that makes LDTs from leading diagnostic test providers available to physicians across the United States. Appistry CloudDx was launched at the 2014 ASCO Annual Meeting held in Chicago May 30-June 3, 2014.

CancerSelect targets 120 genes of clinical and biological importance to cancer, providing information that can help physicians individualize treatment to a patient's cancer. The CancerSelect panel is sequenced in PGDx's CLIA-certified laboratory, and the analysis is conducted using PGDx's proprietary algorithms that provide extremely high coverage, copy number analyses for 63 genes, and translocation analysis for 17 genes.

Appistry will collaborate with PGDx to deliver a report to participating physicians containing a pathological evaluation of the tumor sample; tumor-specific mutations (alterations and substitutions, amplifications, and translocations); a description of mutated genes and pathways along with biologic and clinical implications; full statistics; and therapeutic, predictive, and prognostic information and references, as well as referral information for ongoing clinical trials that might be relevant based on the analysis results.

Appistry CloudDx streamlines and simplifies the workflow associated with genomics-based testing, which has been limited in its impact, partly because it requires organizations to amass infrastructure and expertise to deliver relevant results that are usable by physicians. Appistry CloudDx provides a single web dashboard for ordering and tracking the progress of tests and orchestrates the data flow between test providers such as PGDx and requesting physicians and hospitals, thereby ensuring that data and physical samples are transferred and securely managed in accordance with HIPAA and CLIA guidelines.

"PGDx is committed to applying the latest genomics technology to deliver comprehensive, reliable, unbiased analyses of cancer-related mutations," said Antony Newton, chief commercial officer at PGDx. "Making CancerSelect available through Appistry CloudDx will extend our reach, enabling our panel to be utilized more broadly by community physicians looking to provide the best diagnostic and treatment options to their patients."

"Appistry's aim is to enable physicians everywhere to implement genomics-based tests, regardless of geography, institutional size, or medical system affiliation," said Kevin Haar, chief executive officer of Appistry. "We are excited that PGDx's CancerSelect test will be available as the first offering in Appistry CloudDx, as it is a great example of the type of high-quality, leading-edge medicine that physicians need in order to deliver genomically enhanced medicine to their patients."

Appistry will be demonstrating CloudDx at Booth #16152 at the 2014 ASCO Annual Meeting in Chicago May 30-June 3, 2014. More information about Appistry CloudDx can be found at appistry.com/gem. More information about CancerSelect can be found at personalgenome.com/cancerselect.